Sensei Biotherapeutics, Inc. reported significant financial changes in its latest 10-Q filing for the quarter ending March 31, 2026, primarily driven by its recent acquisition of Faeth Therapeutics. The company recorded a net loss of $170.2 million for the quarter, a substantial increase from the $6.9 million loss reported in the same period last year. This increase is largely attributed to $133 million in acquired in-process research and development expenses related to the acquisition, alongside heightened research and development and general administrative costs.
Total operating expenses surged to $170.6 million, compared to $7.3 million in the prior year, reflecting the integration of Faeth's operations. Research and development expenses rose to $18 million from $3.7 million, while general and administrative expenses increased to $19.7 million from $3.5 million. The company also reported a significant increase in stock-based compensation expenses, which included $12.9 million related to the accelerated vesting of Faeth employee stock options.
In terms of liquidity, Sensei Biotherapeutics ended the quarter with $202.8 million in cash, cash equivalents, and marketable securities, a notable increase from $21.5 million at the end of 2025. This includes $200 million raised through a private placement of Series B Non-Voting Redeemable Convertible Preferred Stock, which is expected to support ongoing clinical trials for its lead program, PIKTOR, an investigational therapy targeting the PI3K/AKT/mTOR pathway in cancer treatment.
The company’s operational metrics indicate a strategic shift following the acquisition, with plans to advance PIKTOR through ongoing clinical trials. Sensei anticipates topline data from its Phase 2 trial in advanced endometrial cancer in the second half of 2026, and it has initiated a Phase 1b/2 trial in HR+/HER2- advanced breast cancer. Despite the current financial losses, the company believes its existing capital will be sufficient to fund operations through these critical milestones.
Looking ahead, Sensei Biotherapeutics acknowledges the need for additional financing to support its operations and strategic initiatives. The company plans to finance its activities through a combination of equity offerings, debt financing, and potential collaborations. However, it also recognizes the risks associated with its ability to raise capital and the uncertainties inherent in the biotechnology sector, particularly regarding the successful development and commercialization of its product candidates.
About Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics is a clinical-stage biotech focused on developing next-generation cancer immunotherapies. Using its TMAb platform, it creates highly selective biologics that modulate the tumor microenvironment by targeting immune checkpoints like VISTA. Its products aim to enhance anti-tumor immune responses, often in combination with existing therapies, serving patients with various solid tumors through innovative, tumor-specific mechanisms.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.